$ILNS company overview inside! Intellect Neuros

$ILNS company overview inside!

Intellect Neurosciences Inc. is a New York based biopharmaceutical company engaged in the discovery and development of a new breed of innovative “disease-modifying” therapeutic drugs designed to slow, arrest and ultimately prevent Alzheimer's disease and other serious neurological disorders.

Intellect is focused on proteinopathies, and its pipeline includes small neuroprotective molecules and neoepitope-based immunotherapy approaches, including monoclonal antibodies, antibody drug conjugates and vaccines targeting beta amyloid and abnormal tau proteins.  Dr. Daniel Chain, the company's  Chairman and CEO, was the first in the biopharmaceutical industry to focus on preventing the accumulation and neurotoxicity of soluble amyloid beta as an approach to treating and preventing Alzheimer’s disease. By targeting the first step in the neurodegenerative process, this approach has the potential to slow, arrest or even prevent the disease.

Utilizing a streamlined team, Intellect's activities resulted in the development of several drugs, which are now licensed and in advanced clinical trials by large pharmaceutical companies, as well as an extremely valuable IP portfolio that is the envy of many, much larger pharmaceutical companies.  Moreover, Intellect has established a truly pre-eminent international network among foremost industry leaders.

The company has an internal preclinical and clinical-stage drug pipeline backed by strong intellectual property across the globe and across diversified technologies.